HanchorBio, a Taiwan-based, clinical-stage biotechnology company focused on immune-oncology and next-generation multi-specific immunotherapies, said on Friday that an abstract detailing preclinical data on HCB301, the company's novel tri-specific anti-cancer fusion protein, has been accepted for poster presentation at the Society for Immunotherapy of Cancer's (SITC) 40th Anniversary Annual Meeting.

The meeting will take place from 5-9 November 2025 in National Harbor, Maryland.

HanchorBio's accepted abstract is titled 'A Novel Tri-Specific Fc Fusion Protein Targeting PD-L1, CD47, and TGF beta Remodels the Tumor Microenvironment and Enhance Anti-Tumor Immunity'.

Scheduled for Saturday, 8 November 2025, the presentation will highlight preclinical efficacy and safety data supporting HCB301's potential as a first-in-class immune-enhancing biologic that targets key mechanisms of tumour immune evasion.

The abstract will also be published in the Journal for ImmunoTherapy of Cancer (JITC) in February 2026 as part of the SITC 2025 Final Supplement.